Oncolytics Biotech
ONCY
36 hedge funds and large institutions have $2.59M invested in Oncolytics Biotech in 2020 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 10 increasing their positions, 6 reducing their positions, and 6 closing their positions.
77% more capital invested
Capital invested by funds: $1.46M → $2.59M (+$1.13M)
67% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 6
0.56% more ownership
Funds ownership: 1.95% → 2.51% (+0.56%)
0% more funds holding
Funds holding: 36 → 36 (0)
0% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$387K |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$270K |
| 3 |
MWNA
Marshall Wace North America
New York
|
+$142K |
| 4 |
IAIM
International Assets Investment Management
Orlando,
Florida
|
+$65.6K |
| 5 |
VF
Virtu Financial
New York
|
+$46.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WS
Wedbush Securities
Los Angeles,
California
|
-$189K |
| 2 |
JP Morgan Chase
New York
|
-$101K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$39K |
| 4 |
FDCDDQ
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
|
-$9.58K |
| 5 |
CCM
Chiron Capital Management
Tallahassee,
Florida
|
-$6K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BCV
26
Banque Cantonale Vaudoise
Lausanne,
Switzerland
| $3K | – | – | – |
|
27
Wells Fargo
San Francisco,
California
| $2K | -$2.4K | -1,000 | -50% |
|
28
Fifth Third Bancorp
Cincinnati,
Ohio
| $2K | – | – | – |
|
|
NFG
29
Next Financial Group
Houston,
Texas
| $2K | – | – | – |
|
|
SN
30
Sittner & Nelson
Eugene,
Oregon
| $2K | +$2.4K | +1,000 | New |
|
|
CAAS
31
Capital Asset Advisory Services
Williamston,
Michigan
| $1K | +$599 | +250 | New |
|
|
WS
32
Wedbush Securities
Los Angeles,
California
| – | -$189K | -111,600 | Closed |
|
|
33
Citadel Advisors
Miami,
Florida
| – | -$39K | -23,139 | Closed |
|
|
34
JP Morgan Chase
New York
| – | -$101K | -16,483 | Closed |
|
|
CCM
35
Chiron Capital Management
Tallahassee,
Florida
| – | -$6K | -3,500 | Closed |
|
36
Bank Julius Baer & Co
Zurich,
Switzerland
| – | -$1K | -750 | Closed |
|
37
1832 Asset Management
Toronto,
Ontario, Canada
| – | -$1.01K | -421 | -99% |
|
|
WWM
38
Wolff Wiese Magana
Carslbad,
California
| – | +$74 | +31 | New |
|
ONCY Hedge Fund Activity: Q4 2020 in Review
36 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Oncolytics Biotech (ONCY) for Q4 2020, worth a combined $2.59M — up 77% from $1.46M a quarter earlier.
Fund positioning in ONCY was balanced in Q4 2020: 6 funds opened new positions, 6 closed out, 10 added to existing stakes and 6 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $387K. The largest seller was Wedbush Securities, exiting entirely with an estimated $189K sold.
- 36 institutional investors held Oncolytics Biotech (ONCY) as of Q4 2020, unchanged from Q3 2020.
- Funds reported $2.59M of Oncolytics Biotech stock for Q4 2020, up 77% quarter-over-quarter.
- 6 funds opened new Oncolytics Biotech positions in Q4 2020 and 6 closed out, a net change of 0 holders.
- The largest Oncolytics Biotech buyer in Q4 2020 was Renaissance Technologies, an estimated $387K added.
- The largest Oncolytics Biotech seller in Q4 2020 was Wedbush Securities, an estimated $189K sold.
Based on aggregated 13F filings for Q4 2020.